Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer

The FDA on Thursday gave its full approval to a combination of Keytruda and TKI inhibitor Lenvima to treat second-line or later patients with advanced endometrial carcinoma without a genetic mismatch repair deficiency or high microsatellite instability, the drugmakers said Thursday.